home / stock / azn / azn articles

AZN Articles, AstraZeneca PLC - From 12/01/23

Stock Information
Company Name: AstraZeneca PLC
Stock Symbol: AZN
Market: NYSE
Website: astrazeneca.com
Menu
AZN AZN Quote AZN Short AZN News AZN Articles AZN Message Board
Get AZN Alerts

News, Short Squeeze, Breakout and More Instantly...
AstraZeneca Stops Two Lokelma Late-Stage Trials After Evaluating Potential Benefits | Benzinga

AstraZeneca Plc (NASDAQ: AZN) discontinued the STABILIZE-CKD and DIALIZE-Outcomes Phase 3 evidence trials for Lokelma (sod...
Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry | Benzinga

In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry expert...

US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges | Benzinga

The U.S. Centers for Disease Control and Prevention (CDC) released more than 77,000 additional doses of Beyfortus (nirsevimab), a respira...

FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug | Benzinga

FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of ad...
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca | Benzinga

The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally a...

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca | Benzinga

Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously anno...

AstraZeneca's Flagship Cancer Drug Imfinzi Fails On Main Goal In Lung Cancer Trial When Combined With Chemoradiotherapy | Benzinga

AstraZeneca Plc (NASDAQ: AZN) said its PACIFIC-2 Phase 3 trial for Imfinzi (durvalumab) concurrently administered with chemoradiothe...
Investigating AstraZeneca's Standing In Pharmaceuticals Industry Compared To Competitors | Benzinga

In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this artic...

Traders Hold Breath For Powell's Remarks, Bitcoin's Wild Ride Unleashed: What's Driving Markets Thursday? | Benzinga

The stock markets is in a lackluster session on Thursday, with traders eagerly awaiting more clues on monetary policy from Fed Chair Jerome Powell,...

AstraZeneca Joins Anti-Obesity Race Dominated By Eli Lilly And Novo Nordisk, Reports Mixed Q3 Earnings | Benzinga

AstraZeneca Plc (NASDAQ: AZN) has reported Q3 FY23 core EPS of $1.73, up 4% Y/Y (+9% on constant currency). On the ADR basis, core e...
Previous 10 Next 10